证券代码：600252 证券简称：中恒集团 公告编号：临 2026-8 广西梧州中恒集团股份有限公司 关于控股孙公司纳米炭铁混悬注射液联合放疗 II 期 临床试验获得伦理批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"） 控股子公司重庆莱美药业股份有限公司（以下简称"莱美药业"）之子公司四川 瀛瑞医药科技有限公司（以下简称"瀛瑞医药"）自主研发的"纳米炭铁混悬注 射液"（以下简称"纳米炭铁"）于近期在四川大学华西医院顺利通过了伦理审 查并收到了临床试验伦理审查委员会的正式批件，标志着纳米炭铁联合放疗正式 进入 II 期临床试验阶段。现将相关情况公告如下： 一、纳米炭铁临床试验进展情况 截至本公告披露日，瀛瑞医药对纳米炭铁的累计研发费用化 9,805.85 万元人 民币（数据未经审计）。 三、风险提示 瀛瑞医药将按国家临床试验的相关要求组织开展纳米炭铁联合放疗的 II 期 临床试验，药品研发是项长期工作，受到技术、审批、政策等多方面因素的影响， II ...

Core Viewpoint - Zhongheng Group announced that its subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has successfully passed the ethical review for its independently developed "Nano Carbon Iron Suspension Injection," marking the entry into Phase II clinical trials in collaboration with radiotherapy [1] Group 1 - The "Nano Carbon Iron Suspension Injection" has received formal approval from the Clinical Trial Ethics Review Committee [1] - The clinical trials are being conducted at West China Hospital of Sichuan University [1] - This development signifies a significant advancement in the company's research and development efforts in the pharmaceutical sector [1]

格隆汇1月29日丨中恒集团(600252.SH)公布， 公司预计2025年年度实现归属于母公司所有者的净利润 为-4.5亿元到-2.5亿元。预计2025年年度实现归属于母公司所有者的扣除非经常性损益的净利润为-4亿元 到-2亿元。 (二)非经营性损益的影响。1.公司本期将结构化主体纳入合并财务报表范围，因相关资产公允价值变动 形成损失约6000万元；2.公司委托理财产品本期公允价值下跌确认相关损失约1000万元。 (一)主营业务影响。1.公司主要产品销量及单价下降，导致公司营业收入和毛利同比减少；2.控股子公 司业绩未达预期，其商誉减值及其业绩预计减少公司净利润约1.1亿元；3.公司对预期将出现信用风险的 债权进行分析判断，并计提相应的信用减值损失约8000万元；4.公司对闲置设备、不动产等出现减值迹 象的长期资产进行减值测试并确认减值准备约5500万元。 本期业绩预亏的主要原因： ...

Core Viewpoint - Zhongheng Group has announced an annual performance forecast indicating a significant net loss for 2025, with expected net profit attributable to shareholders ranging from -250 million to -450 million yuan, and a net profit excluding non-recurring losses expected to be between -200 million and -400 million yuan [1] Group 1: Main Business Impact - The decline in sales volume and unit price of the company's main products has led to a year-on-year decrease in operating revenue and gross profit [1] - The performance of a controlling subsidiary did not meet expectations, resulting in goodwill impairment and a projected reduction in net profit by approximately 110 million yuan [1] - The company has assessed credit risks on expected non-performing receivables, leading to a provision for credit impairment losses of about 8 million yuan [1] - Impairment tests on idle equipment and long-term assets showing signs of impairment have resulted in a recognition of impairment provisions of approximately 5.5 million yuan [1] Group 2: Non-Operating Loss Impact - The company has included structured entities in its consolidated financial statements, resulting in a loss of approximately 60 million yuan due to changes in the fair value of related assets [1] - The fair value decline of entrusted financial products has led to a recognition of related losses of about 10 million yuan [1]

Core Viewpoint - Guangxi Wuzhou Pharmaceutical (Group) Co., Ltd. under Zhongheng Group's "Morning Bell" brand is set to be included in the 2025 China Consumer Brand List, marking a significant milestone in its brand development and recognition as a national quality consumer brand [1][2]. Group 1 - The 2025 China Consumer Brand List is the first national-level consumer brand evaluation led by the Ministry of Industry and Information Technology, aimed at promoting consumption upgrades and cultivating globally recognized brands [1]. - The "Morning Bell" brand, registered in 1986, is associated with the flagship product, Thrombolytic Injection (freeze-dried), which has received multiple awards, including the National Science and Technology Progress Award (Second Class) and the China Patent Excellence Award [1]. - The company emphasizes its development philosophy of "Creating Quality Chinese Medicine to Protect People's Health" and integrates traditional Chinese medicine wisdom with modern pharmaceutical technology [1]. Group 2 - Wuzhou Pharmaceutical is committed to increasing R&D investment through its national-level technology center and collaborative innovation platforms, focusing on modernizing and refining the "Morning Bell" brand products [2]. - The company aims to leverage its inclusion in the China Consumer Brand List to enhance brand development, accelerate innovation-driven growth, and expand its market presence [2].

Group 1 - The Ministry of Industry and Information Technology has announced the 2025 list of China's consumer brands, with Guangxi Wuzhou Pharmaceutical Group Co., Ltd.'s "Morning Bell" brand successfully selected, marking a significant milestone in the brand's development [2] - "Morning Bell" brand, registered in 1986, is associated with the flagship product, Thrombolytic Injection (lyophilized), which is well-regarded in the cardiovascular field due to its advanced freeze-drying technology and comprehensive quality control system [2][3] - The brand has achieved national market coverage across 31 provinces and cities, and has been included in the 2025 list of "China's 500 Most Valuable Brands," with a brand value assessment of 8.216 billion RMB, ranking 489th [3] Group 2 - The company emphasizes a development philosophy of "Creating Good Chinese Medicine for People's Health," focusing on a full industry chain quality control system and integrating traditional Chinese medicine wisdom with modern pharmaceutical technology [3] - The company has invested in research and development, leveraging a national-level technology center and collaborative innovation platforms to enhance the modernization and refinement of "Morning Bell" products, thereby maintaining market advantages [3] - Moving forward, the company aims to deepen brand development, accelerate innovation-driven growth, and expand its national market presence while upholding the essence of traditional medicine [3]

Core Viewpoint - The report highlights the growth of industrial enterprises in Guangxi Zhuang Autonomous Region, indicating a positive trend in the industrial sector with a year-on-year increase in the number of enterprises [1]. Group 1: Industrial Enterprises in Guangxi - As of January-November 2025, the number of industrial enterprises in Guangxi reached 10,535, an increase of 239 enterprises compared to the same period last year, representing a growth rate of 2.32% [1]. - The industrial enterprises accounted for 2% of the national total, reflecting Guangxi's contribution to the overall industrial landscape in China [1]. Group 2: Industry Research and Consulting - Zhiyan Consulting, a leading industry consulting firm in China, has been deeply engaged in industry research for over a decade, providing comprehensive industry research reports, business plans, feasibility studies, and customized services [1]. - The firm emphasizes its professional approach, quality service, and keen market insights to empower investment decisions [1].

Group 1 - Defu Technology plans to acquire at least 51% of Huiru Technology through cash purchase and capital increase, making Huiru a subsidiary [1] - Huiru Technology specializes in the research, production, and sales of high-performance electrolytic copper foil, including lithium battery copper foil and electronic circuit copper foil [1] Group 2 - Medike's shareholder plans to reduce holdings by no more than 1% of the company's shares, amounting to approximately 410.93 million shares [2] - Huadong Medicine's subsidiary, Daor Biotechnology, has its product DR10624 included in the list of breakthrough therapeutic varieties, targeting severe hypertriglyceridemia [3] Group 3 - Fangsheng Pharmaceutical received a notice of non-compliance from the Hunan Provincial Drug Administration regarding its raw material drug production [4] - Yanjing Co. is planning a major asset restructuring, leading to a temporary suspension of its stock [5] - Xianle Health intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange [6] Group 4 - Huate Gas shareholders plan to collectively reduce their holdings by no more than 2% of the company's shares [7] - Hangyu Technology plans to sell up to 752,800 repurchased shares to supplement working capital [8] Group 5 - Sichuan Electronics expects a net loss of between 265 million to 340 million yuan for the year 2025 [10] - Jinzongzi Wine anticipates a net loss for the 2025 fiscal year, although the loss is expected to narrow compared to the previous year [11] - Hebang Bio forecasts a net loss for 2025 due to anticipated asset impairment provisions [12] Group 6 - Dechang Co. expects a net profit decrease of 51% to 61% for 2025, estimating a profit of 160 million to 200 million yuan [13] - Kosen Technology and Weiyuan Co. both project net losses for 2025 [14][15] - Xiantan Co. reported a chicken product sales revenue of 530 million yuan in December 2025, with a year-on-year increase of 9.41% [16] Group 7 - Shangluo Electronics' application for issuing convertible bonds has been accepted by the Shenzhen Stock Exchange [17] - Zhongheng Group anticipates a net loss for 2025 [18]

Core Viewpoint - Zhongheng Group (600252) anticipates a negative net profit for the fiscal year 2025, indicating a significant operational loss [1] Group 1: Financial Performance - The company reported a drastic decline in net profit for 2024, with a year-on-year decrease of 547.14% to -377 million yuan, marking the second annual loss since its listing [1][2] - In the first three quarters of 2025, the company achieved total revenue of 1.948 billion yuan, a year-on-year increase of 1.10%, and a net profit of 24.64 million yuan, up 119.61% [2] - Despite the profit growth in early 2025, the company expects a negative net profit for the entire year, indicating substantial losses in the fourth quarter [2] Group 2: Key Financial Metrics - The company's gross margin plummeted from 61.45% in 2023 to 43.21% in 2024, and further down to 31.92% in the first three quarters of 2025 [2] - The net profit margin deteriorated from 0.98% in 2023 to -24.27% in 2024, remaining at -0.48% in the first three quarters of 2025 [2] Group 3: Debt and Financial Position - As of the end of the third quarter of 2025, short-term borrowings increased by 21.4% compared to the end of the previous year, accounting for a 2.43% rise in total assets [3] - Long-term borrowings rose by 47.52%, contributing to a 1.94% increase in total assets [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 经广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）财务部门初步测算，预计2025年年 度归属于上市公司股东的净利润为负值，公司2025年年度经营业绩将出现亏损。 公司将严格遵循《上海证券交易所股票上市规则》等相关规定，加快推进财务核算工作，尽快披露2025 年年度业绩预告。最终财务数据请以公司正式披露的2025年年度报告为准。 公司指定的信息披露媒体为《中国证券报》《上海证券报》《证券时报》《证券日报》及上海证券交易 所网站（www.sse.com.cn），有关公司信息均以公司在上述指定媒体披露信息为准。敬请广大投资者理 性投资，注意投资风险。 特此公告。 广西梧州中恒集团股份有限公司 董事会 2026年1月12日 ...